Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up
Key Points
Overall survival significantly improved with brentuximab vedotin plus chemotherapy, marking a positive impact on treatment outcomes.
Five-year follow-up revealed favorable results for younger patients receiving this combined therapy over chemotherapy alone.
Subgroup analysis focused on various demographics and risk factors to assess treatment efficacy and safety parameters.
Findings highlight the effectiveness of brentuximab vedotin in enhancing survival prospects for anaplastic large cell lymphoma patients.
Like
Bookmark
Share
View Full Paper
Like
Bookmark
Share
View Full Paper
Cite This Study
Domingo-Domenech et al. (Wed,) studied this question.
Korrektur: Brentuximab vedotin plus Chemotherapie zur Behandlung des frontalen systemischen anaplastischen großzelligen Lymphoms: Subgruppenanalyse der ECHELON-2-Studie nach 5 Jahren Nachbeobachtung | Synapse